Answers are grounded in this paper and cite their sources.
The transition from the IVDD directive to the IVDR regulation (EU) 2017/746 has radically transformed the European landscape of in vitro diagnostic medical devices, addressing the challenges of personalized medicine and the vulnerabilities exposed by the Poly Implant Prothèse (PIP) scandal, which exclusively concerned general medical devices but ultimately paved the way for the reform of both directives. This overhaul has placed Notified Bodies (NBs) at the center of the system, extending their mandatory oversight from 8% to over 80% of devices on the market through a risk-based classification. A documentary search within the EUR-Lex and NANDO registries alongside a PubMed bibliographic analysis (2017–2026) reveals a severe structural imbalance: the strict requirements of Annex VII contracted the active network to just 19 units, slowing down certification timelines. The analysis demonstrates that these delays are further compounded by new intersectoral procedures, such as mandatory EMA consultations for companion diagnostics (CDx) and review timelines by EU Reference Laboratories (EURLs) for Class D devices. The discussion of these data underscores that while the successive transitional extensions introduced first by Regulation (EU) 2022/112 and subsequently by Regulation (EU) 2024/1860 temporarily averted a lack in healthcare supplies, long-term market stability cannot rely on continuous legislative delays but demands an operational optimization of this restricted oversight network.
No takes yet. Share an insight, caveat, or question.
Piras et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: